Outreach

Your Outreach Librarian can help facilitate evidence-based practise for all members of staff, as well as assisting with academic study and research. We can help with literature searching, obtaining journal articles and books, and setting up individual current awareness alerts. We also offer one-to-one or small group training in literature searching, accessing electronic journals, and critical appraisal.

Email Helen Pullen

library@UHBristol.nhs.uk

Literature Searching

We provide a literature searching service for any library member. For those embarking on their own research it is advisable to book some time with one of the librarians for a 1 to 1 session where we can guide you through the process of creating a well-focused literature research and introduce you to the health databases access via NHS Evidence. Please email requests to library@UHBristol.nhs.uk

Books

Books can be searched for using SWIMS our online catalogue at www.swims.nhs.uk. Up to 12 books can be borrowed at one time. Books can be renewed in person, over the phone or on the SWIMS website. Short Loan books cannot be renewed but may be re-issued on return.

Inter-Library Loans

Books and journals that are not available on site or electronically may be requested from other locations. Please email requests to: ills@UHBristol.nhs.uk
Contents

1:  Tables of Contents from January’s Cardiac Journals

2:  New NICE Guidance

3:  Latest relevant Systematic Reviews from the Cochrane Library.

4:  NHS Behind the Headlines

5:  New activity in Uptodate
Tables of Contents from relevant journals

JACC

Journal of the American College of Cardiology
February 17, 2015, Vol. 65, No. 6

Ischemic Brain Lesions After Carotid Artery Stenting Increase Future Cerebrovascular Risk
Henrik Gensicke, MD, H. Bart van der Worp, PhD, Paul J. Nederkoorn, PhD, Sumairah Macdonald, PhD, Peter A. Gaines, MBChB, Aad van der Lugt, MD, Willem P. Th. M. Mali, MD, Philippe A. Lyer, MD, Nils Peters, MD, Roland L. Featherstone, PhD, Gert J. de Borst, MD, Stefan T. Engelter, MD, Martin M. Brown, MD and Leo H. Bonati, MD

Supplemental materials

Original Investigation: Editorial Comment

Flights From Wonder: The Search for Meaning in Diffusion-Weighted Brain Lesions
William A. Gray, MD

Original Investigation

A Randomized Trial of a Dedicated Bifurcation Stent Versus Provisional Stenting in the Treatment of Coronary Bifurcation Lesions
Philippe Généreux, MD, Indulis Kumsars, MD, Maciej Lesiak, MD, Annapoorna Kini, MD, Géza Fontos, MD, Ton Slagboom, MD, Imre Ungi, MD, PhD, D. Christopher Metzger, MD, Joanna J. Wykrzykowska, MD, PhD, Pieter R. Stella, MD, PhD, Antonio L. Bartorelli, MD, William F. Fearon, MD, Thierry Lefèvre, MD, Robert L. Feldman, MD, Laura LaSalle, MPH, Dominic P. Francesce, MPH, Yoshinobu Onuma, MD, PhD, Maik J. Grundeken, MD, Hector M. Garcia-Garcia, MD, PhD, Linda L. Laak, BSN, Donald E. Cutlip, MD, Aaron V. Kaplan, MD, Patrick W. Serruys, MD, PhD and Martin B. Leon, MD

Supplemental materials

Original Investigation: Editorial Comment

Treatment of Bifurcation Lesions: Less Is More
John A. Bittl, MD

Original Investigation

ApoB-100–Related Peptide Vaccine Protects Against Angiotensin II–Induced Aortic Aneurysm Formation and Rupture
Tomoyuki Honjo, MD, PhD, Kuang-Yuh Chyu, MD, PhD, Paul C. Dimayuga, PhD, Juliana Yano, BS, Wai Man Lio, BS, Portia Trinidad, BS, Xiaoning Zhao, PhD, Jianchang Zhou, MD, PhD, Shuang Chen, PhD, Bojan Cercek, MD, PhD, Moshe Arditi, MD and Prediman K. Shah, MD

Supplemental materials

Original Investigation: Editorial Comment

Vaccination Against Atherosclerosis and Abdominal Aortic Aneurysm
Erling Falk, MD, PhD

Original Investigation

Irreversible Triggers for Hypertrophic Cardiomyopathy Are Established in the Early Postnatal Period
Leah Cannon, PhD, Ze-Yan Yu, MBBS, PhD, Tadeusz Marciniec, PhD, Ashley J. Waardenberg, PhD, Siiri E. Jismaa, PhD, Vesna Nikolova-Krstevski, PhD, Elysa Neist, B Biotech (Hons), Monique Ohanian, BMedSci (Hons), Min Ru Qiu, MBBS, PhD, Stephen Rainer, MBBS, Richard P. Harvey, PhD, Michael P. Feneley, MD, Robert M. Graham, MD and Diane Fatkin, MD

Supplemental materials

Original Investigation: Editorial Comment

Hypertrophic Cardiomyopathy: Can the Horse Be Put Back in the Barn?
Matthew T. Wheeler, MD, PhD and Euan A. Ashley, DPhil
Original Investigation
Abnormal Exercise Response in Long-Term Survivors of Hodgkin Lymphoma Treated With Thoracic Irradiation: Evidence of Cardiac Autonomic Dysfunction and Impact on Outcomes
John D. Groarke, MBCh, MPH, Varsha K. Tanguturi, MD, Jon Hainer, BS, Josh Klein, BA, Javid J. Moslehi, MD, Andrea Ne, MD, Daniel E. Forman, MD, Marcelo F. Di Carli, MD and Anju Nohria, MD
Supplemental materials
Original Investigation: Editorial Comment
Screening for Cardiac Autonomic Dysfunction Among Hodgkin Lymphoma Survivors Treated With Thoracic Radiation∗
Kirsten K. Ness, PT, PhD and Gregory T. Armstrong, MD, MSCE
Highlights of the Year
Editor-in-Chief's Picks From 2014: Part One
Valentin Fuster, MD, PhD
The Present and Future: Review Topic of the Week
Revascularization in Severe Left Ventricular Dysfunction
Eric J. Velazquez, MD and Robert O. Bonow, MD, MS
Fellows-in-Training & Early Career Page
Research During Fellowship: Walking the Tight Rope
Smita I. Negi, MD and Edward Koifman, MD
Letters
No Evidence of an Upper Threshold for Mortality Benefit at High Levels of Cardiorespiratory Fitness
David I. Feldman, BS, Mouaz H. Al-Mallah, MD, Steven J. Keteyian, PhD, Clinton A. Brawner, PhD, Theodore Feldman, MD, Roger S. Blumenthal, MD and Michael J. Blaha, MD, MPH
Cholesterol Crystals Associate With Coronary Plaque Vulnerability In Vivo
Yu Kataoka, MD, Rishi Puri, MBBS, PhD, Muhammad Hammadah, MD, Bhanu Duggal, MD, Kiyoko Uno, MD, PhD, Samir R. Kapadia, MD, E. Murat Tuzcu, MD, Steven E. Nissen, MD and Stephen J. Nicholls, MBBS, PhD
Does Body Adiposity Better Predict Obesity-Associated Cardiometabolic Risk Than Body Mass Index?
Javier Gómez-Ambrosi, PhD, Victoria Catalán, PhD, Amaia Rodriguez, PhD, Javier Salvador, MD, PhD and Gema Frühbeck, RNutr, MD, PhD
Reply: Does Body Adiposity Better Predict Obesity-Associated Cardiometabolic Risk Than Body Mass Index?
Alvin Chandra, MD and Aslan T. Turer, MD, MHS
Serial Angiographic Studies of Culprit Lesions Before MI
William C. Little, MD and John Ambrose, MD

Circulation

February 10, 2015, Volume 131, Issue 6

Clinical Summaries

Circulation: Clinical Summaries: Original Research Put Into Perspective for the Practicing Clinician
Circulation. 2015;131:517-518, doi:10.1161/CIR.0000000000000162
Making Sense of Genome-Wide Association Studies: Integrating Genetic Variation With Gene Expression to Derive Functional Mechanisms Underlying Disease Risk
Hsiao-Huei Chen and Alexandre F. R. Stewart
Circulation. 2015;131:519-521, published online before print December 22
2014, doi:10.1161/CIRCULATIONAHA.114.014634

**What the Dead Can Teach the Living:** Systemic Nature of Heart Failure With Preserved Ejection Fraction
Dalane W. Kitzman, Bharathi Upadhyia, and Sujethra Vasu
Circulation. 2015;131:522-524, published online before print December 31
2014, doi:10.1161/CIRCULATIONAHA.114.014420

**How to Repeat a Success and Control a Bad Influence**
Göran Hansson
Circulation. 2015;131:525-527, published online before print December 31
2014, doi:10.1161/CIRCULATIONAHA.114.014560

**Original Articles**

**Coronary Heart Disease**
Interaction of Impaired Coronary Flow Reserve and Cardiomyocyte Injury on Adverse Cardiovascular Outcomes in Patients Without Overt Coronary Artery Disease
Viviany R. Taqueti, Brendan M. Everett, Venkatesh L. Murthy, Mariya Gaber, Courtney R. Foster, Jon Hainer, Ron Blankstein, Sharmila DORBALA, and Marcelo F. Di Carli
Circulation. 2015;131:528-535, published online before print December 5
2014, doi:10.1161/CIRCULATIONAHA.114.009716

**Genetics**
Integromic Analysis of Genetic Variation and Gene Expression Identifies Networks for Cardiovascular Disease Phenotypes
Chen Yao, Brian H. Chen, Roby Joehanes, Burcak Otlu, Xiaoling Zhang, Chunyu Huan, Oznur Tastan, L. Adrienne Cupples, James B. Meigs, Caroline S. Fox, Jane E. Freedman, Paul Courchesne, Christopher J. O’Donnell, Peter J. Munson, Sunduz Keles, and Daniel Levy
Circulation. 2015;131:536-549, published online before print December 22
2014, doi:10.1161/CIRCULATIONAHA.114.010696

**Heart Failure**
Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction
Selma F. Mohammed, Saad Hussain, Sultan A. Mirzoyev, William D. Edwards, Joseph J. Maleszewski, and Margaret M. Redfield
Circulation. 2015;131:550-559, published online before print December 31
2014, doi:10.1161/CIRCULATIONAHA.114.009625

**Vascular Medicine**
Control of the T Follicular Helper–Germlinal Center B-Cell Axis by CD8'Regulatory T Cells Limits Atherosclerosis and Tertiary Lymphoid Organ Development
Marc Clement, Kevin Guedj, Francesco Andreata, Marion Morvan, Laetitia Bey, Jamila Khallou-Laschet, Anh-Thu Gaston, Sandrine Delbos, Jean-Marc Alsac, Patrick Bruneval, Catherine Deschildre, Marie Le Borgne, Yves Castier, Hye-Jung Kim, Harvey Cantor, Jean-Baptiste Michel, Giuseppina Caligiuri, and Antonino Nicoletti
Circulation. 2015;131:560-570, published online before print December 31
2014, doi:10.1161/CIRCULATIONAHA.114.010988

**Valvular Heart Disease**
Endocarditis Pathogen Promotes Vegetation Formation by Inducing Intravascular Neutrophil Extracellular Traps Through Activated Platelets
Chiau-Jing Jung, Chio-Yueh Yeh, Ron-Bin Hsu, Chii-Ming Lee, Chia-Tung Shun, and Jean-San Chia
Circulation. 2015;131:571-581, published online before print December 19
2014, doi:10.1161/CIRCULATIONAHA.114.011432

**CLINICAL PERSPECTIVE**
Recent Advances in Pulmonary Hypertension

Pathophysiology and Treatment of High–Altitude Pulmonary Vascular Disease
Martin R. Wilkins, Hossein-Ardeschir Ghofrani, Norbert Weissmann, Almaz Aldashev, and Lan Zhao
Circulation. 2015;131:582-590, doi:10.1161/CIRCULATIONAHA.114.006977

ECG Challenge Response

ECG Response: February 10, 2015
Circulation. 2015;131:591-592, doi:10.1161/CIRCULATIONAHA.114.015198

Images in Cardiovascular Medicine

Recurrent Right Coronary Artery Occlusion Caused by Cardiac Fibroelastoma Attached to the Aortic Valve
Kavitha Vimalesvaran, Matthew Lumley, Nicholas Child, Simon Redwood, Christopher Blauth, Eike Nagal, and Divaka Perera
Circulation. 2015;131:593-595, doi:10.1161/CIRCULATIONAHA.114.013060

Fungal Endocarditis After Hybrid Periventricular Closure of Muscular Ventricular Septal Defect by Amplatz Occluder in a Child
Sabrina Bressieux-Degueldre, Nicole Sekarski, and Stefano Di Bernardo
Circulation. 2015;131:e339-e340, doi:10.1161/CIRCULATIONAHA.114.011159

Correspondence

Letter by Herzig Regarding Article, “Electronic Cigarettes: A Scientific Review”
Zvi Herzig
Circulation. 2015;131:e341, doi:10.1161/CIRCULATIONAHA.114.012089

Response to Letter Regarding Article, “Electronic Cigarettes: A Scientific Review”
Rachel Grana, Neal Benowitz, and Stanton Glantz
Circulation. 2015;131:e342, doi:10.1161/CIRCULATIONAHA.114.012887

Letter by Psaty et al Regarding Article, “Heart Failure With Recovered Ejection Fraction: Clinical Description, Biomarkers, and Outcomes”
Bruce M. Psaty, Sanjiv J. Shah, and John Gottdiener
Circulation. 2015;131:e343, doi:10.1161/CIRCULATIONAHA.114.012243

Response to Letter Regarding Article, “Heart Failure With Recovered Ejection Fraction: Clinical Description, Biomarkers, and Outcomes”
Anupam Basuray, Benjamin French, Bonnie Ky, Esther Vorovich, Caroline Olt, Nancy Sweitzer Thomas Cappola, and James C. Fang
Circulation. 2015;131:e344, doi:10.1161/CIRCULATIONAHA.114.012888
Focus Issue on acute coronary syndromes and intervention
Volume 36, Issue 6, 07 February 2015
Issue @ a Glance

Acute coronary syndromes and coronary intervention
CardioPulse

CardioPulse articles

EDITORIALS
Can copeptin emerge from the growing shadow of the troponins?

Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution?

Reanalysis or redefinition of the hypothesis?

CURRENT OPINION
The year in cardiology 2014: acute coronary syndromes

Figures & data

The year in cardiology 2014: coronary intervention

FAST TRACK BASIC SCIENCE
★ FAST TRACKEDITOR’S CHOICE ★

Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs

CLINICAL RESEARCH
Acute coronary syndromes
Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study

★ EDITOR’S CHOICE ★
The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial

Abstract

Late acute coronary syndrome 9 months after uneventful transcatheter aortic valve replacement
Marco Amoruso, Stefano Muzzarelli, Tiziano Moccetti, Giovanni B. Pedrazzini

Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy
Leo Timmers, Pieter R. Stella, Pierfrancesco Agostoni
Eur Heart J (2015) 36 (6): 393 DOI: http://dx.doi.org/10.1093/eurheartj/ehu262 First published online: 10 July 2014 (8 pages)

If you require full articles please email Helen Pullen @ library@UHBristol.nhs.uk

New NICE Guidance

Acute coronary syndromes (including myocardial infarction)
http://www.nice.org.uk/guidance/QS68

NICE quality standard [QS68] Published date: September 2014

2 Pathways
Latest relevant Systematic Reviews from the Cochrane Library

Virtual reality for stroke rehabilitation
Kate E Laver, Stacey George, Susie Thomas, Judith E Deutsch, Maria Crotty
Online Publication Date: February 2015

Surgery for small asymptomatic abdominal aortic aneurysms
Giovanni Filardo, Janet T Powell, Melissa Ashley-Marie Martinez, David J Ballard
Online Publication Date: February 2015

Embolisation for pulmonary arteriovenous malformation
Charlie C-T Hsu, Gigi NC Kwan, Shane A Thompson, Hannah Evans-Barns, Mieke L van Driel
Online Publication Date: January 2015

Prosthetic rehabilitation for older dysvascular people following a unilateral transfemoral amputation
Jane Cumming, Steve Barr, Tracey E Howe
Online Publication Date: January 2015

Homocysteine-lowering interventions for preventing cardiovascular events
Arturo J Martí-Carvajal, Ivan Solà, Dimitrios Lathyris
Online Publication Date: January 2015

Beta-adrenergic blockers for perioperative cardiac risk reduction in people undergoing vascular surgery
Katayoun Mostafaei, Rachel Bedenis, Darrell Harrington
Online Publication Date: January 2015

First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension
Hao Xue, Zhuang Lu, Wen Lu Tang, Lu Wei Pang, Gan Mi Wang, Gavin WK Wong, James M Wright
Online Publication Date: January 2015

Aimuousing for acute ischaemic stroke
Weimin Yang, Zhaobo Shi, Hong-Qi Yang, Junfang Teng, Jun Zhao, Guoliang Xiang
Online Publication Date: January 2015

Intervention
Community wide interventions for increasing physical activity
Philip RA Baker, Daniel P Francis, Jesus Soares, Alison L Weightman, Charles Foster
Online Publication Date: January 2015

If you require full articles, or a more enhanced search of any of the below topics please email Helen @ library@UHBristol.nhs.uk

New activity in UpToDate

What's new in cardiovascular medicine
Authors
Gordon M Saperia, MD, FACC
Susan B Yeon, MD, JD, FACC
Brian C Downey, MD, FACC

Disclosures: Gordon M Saperia, MD, FACC Employee of UpToDate, Inc. Susan B Yeon, MD, JD, FACC Employee of UpToDate, Inc. Brian C Downey, MD, FACC Employee of UpToDate, Inc.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

Conflict of interest policy

All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Jan 2015. | This topic last updated: Feb 10, 2015.
The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.

ARRHYTHMIAS

Approval of the direct factor Xa inhibitor edoxaban (January 2015)

The US Food and Drug Administration has approved the oral direct factor Xa inhibitor edoxaban (Savaysa; Lixiana in Japan) for the prevention of stroke in nonvalvular atrial fibrillation and the treatment of venous thromboembolism, based upon earlier randomized trials demonstrating non-inferiority to warfarin [1-3]. Dosing is once daily at a fixed dose without monitoring. There are Boxed Warnings regarding avoidance of edoxaban in patients with atrial fibrillation who have a creatinine clearance >95 mL/minute, spinal/epidural hematoma in patients undergoing neuraxial procedures, and ischemic events following premature discontinuation. (See "Atrial fibrillation: Anticoagulant therapy to prevent embolization" and "Lower extremity deep venous thrombosis: Long-term anticoagulation (10 days to three months)" and "Anticoagulation in acute pulmonary embolism" and "Anticoagulation with direct thrombin inhibitors and direct factor Xa inhibitors", section on 'Edoxaban'.)

Lower risk of fatal bleeding with target specific oral anticoagulants versus warfarin (November 2014)

All anticoagulants carry a risk of bleeding, and the lack of an antidote for direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and the direct thrombin inhibitor dabigatran increases concerns about this risk. Reassuringly, a meta-analysis of 12 randomized trials in patients with atrial fibrillation or venous thromboembolism that compared bleeding risk with these agents versus vitamin K antagonists found lower rates of fatal bleeding, major bleeding, and intracranial bleeding with the direct factor Xa and direct thrombin inhibitors [4]. Individual patient factors continue to play a role in anticoagulant choice and the development of reversal agents for the factor Xa and thrombin inhibitors is underway. (See "Management of bleeding in patients receiving target-specific oral anticoagulants", section on 'Risk of bleeding'.)

The role of digoxin in rate control for patients with AF (August 2014)

The role of digoxin in ventricular rate control in patients with atrial fibrillation (AF) has been limited due to relative poor efficacy and the possibility of an increase in mortality in patients without heart failure. The observational TREAT-AF study evaluated mortality in over 120,000 patients with a recent diagnosis of nonvalvular atrial fibrillation [5]. In this new study, digoxin use was associated with a nearly 25 percent increase in all-cause mortality across all subgroups, including those with and without heart failure. Important limitations of this study include its retrospective design and the absence of a detailed evaluation of the potential impact of digoxin levels. We limit the use of digoxin in AF patients without heart failure to those in whom beta blockers and calcium channel blockers have not achieved adequate rate control and who are not considered candidates for non-pharmacologic therapy to control rate. (See "Control of ventricular rate in atrial fibrillation: Pharmacologic therapy", section on 'Digoxin'.)

Prophylactic ICD implantation for patients with LVEF 30 to 35 percent (July 2014)
Although most studies of prophylactic implantable cardioverter-defibrillator (ICD) implantation have included patients with a left ventricular ejection fraction (LVEF) ≤35 percent, most study patients had LVEF <30 percent, resulting in uncertainty regarding benefit in patients with LVEF between 30 and 35 percent. In a retrospective cohort study using data from two large registries of patients with and without ischemic disease (National Cardiovascular Data Registry of patients who underwent ICD implantation and Get With The Guidelines-Heart Failure patients without an ICD) in which the benefits of ICD implantation were separately evaluated for patients with LVEF <30 percent and those with LVEF 30-35 percent, all-cause mortality was significantly lower in patients with an ICD and any level of LVEF, compared with those without an ICD [6]. These data, although not from a randomized trial, support our recommendation to implant an ICD in patients with heart failure and an LVEF of 35 percent or lower. (See "Primary prevention of sudden cardiac death in heart failure and cardiomyopathy", section on 'LVEF and risk'.)

CONGENITAL HEART DISEASE, ADULT

Angiotensin II receptor blocker versus beta blocker for Marfan syndrome (November 2014)

Studies in patients with Marfan syndrome (MFS) and aortic root dilation have suggested that angiotensin II receptor blocker therapy may be more effective than beta blocker therapy for prevention of further dilation. A randomized trial comparing losartan with atenolol in 608 children and adults with MFS and aortic root dilation found no significant difference in the rate of dilation between the two treatment groups over a three-year period [7]. We recommend beta blocker therapy for patients with MFS with aortic root dilation and suggest addition of an angiotensin II receptor blocker as tolerated. (See "Management of Marfan syndrome and related disorders", section on 'Therapy targeting the renin-angiotensin system'.)

CORONARY ARTERY BYPASS GRAFT SURGERY

Colchicine for prevention of post-cardiac injury syndrome (September 2014)

Colchicine is effective for the prevention and treatment of acute and recurrent pericarditis as well as post-cardiac injury syndrome, but its effectiveness is limited in many patients due to side effects. In the COPPS-2 trial, a randomized trial of colchicine or placebo beginning 48 to 72 hours prior to cardiac surgery, colchicine significantly reduced the occurrence of the post-cardiac injury syndrome at three months but was associated with significantly more adverse effects, primarily gastrointestinal [8]. Based on the collective results of this trial and the first COPPS trial, in which colchicine was begun postoperatively and showed similar reductions in post-cardiac injury syndrome with significantly less GI toxicity, for most patients undergoing cardiac surgery, we suggest a course of colchicine beginning one to three days following surgery to reduce the risk of developing post-cardiac injury syndrome. (See "Post-cardiac injury syndromes", section on 'Prevention'.)

CORONARY HEART DISEASE, ACUTE

Culprit-only or multivessel PCI in patients with STEMI (October 2014)

The optimal revascularization strategy with percutaneous coronary intervention (PCI) is not known for the 40 to 50 percent of patients with acute ST-elevation myocardial infarction (STEMI) found to have significant lesions (≥50 percent luminal narrowing) in addition to the lesion responsible for the
acute MI. A 2014 meta-analysis of three randomized trials found that the risks of subsequent revascularization and nonfatal MI were lower with multivessel compared to culprit only PCI [9]. For many patients with non-culprit lesions, we now proceed with multivessel revascularization at the time of primary PCI. We do not perform immediate non-culprit PCI when patients meet the following criteria: chronic kidney disease; administration of a large contrast volume; less than TIMI III flow in the culprit vessel after optimal PCI; complex non-culprit stenosis; patient, operator, or health care team fatigue; anticipated need for coronary artery bypass graft surgery or valve surgery in the near future; severe comorbidities. (See "Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management", section on 'Non-culprit PCI'.)

2014 ACC/AHA guideline on NSTE-ACS (October 2014)

The American College of Cardiology/American Heart Association (ACC/AHA) has updated its guideline for the management of patients with non-ST elevation acute coronary syndromes (NSTE-ACS) [10]. We agree with recommendations made in this guideline, which covers multiple aspects of care of patients with NSTE-ACS. Changes from the 2011 version of this guideline include no longer recommending platelet function testing to determine platelet inhibitory response, or genotyping for a CYP2C19 loss of function variant, in patients with NSTE-ACS. (See "Clopidogrel resistance and clopidogrel treatment failure", section on 'Recommendations of others'.)

Routine thrombus aspiration in STEMI not helpful (September 2014)

Intracoronary thrombus is found in the majority of patients with ST-elevation myocardial infarction (STEMI), and higher burdens of thrombus are associated with worse outcomes. Thrombus aspiration prior to percutaneous intervention (PCI) can reduce the thrombus burden; however, there has been conflicting evidence on whether this improves outcomes. A prior meta-analysis of randomized trials indicated a reduced risk of all-cause mortality with aspiration thrombectomy, although there were some concerns about the analysis and generalizability of the underlying trials. The TASTE trial, not included in the meta-analysis, randomly assigned 7244 patients to routine thrombus aspiration followed by PCI or to PCI only. Previously reported 30-day results found no difference in the primary end point of death from any cause. In a newly published report of outcomes at one year from the TASTE trial, there was similarly no difference in mortality for patients treated with and without thrombectomy (5.3 versus 5.6 percent) [11]. Based on these results, we no longer suggest the routine use of thrombus aspiration prior to PCI in STEMI patients. It is reasonable to continue to use aspiration thrombectomy in patients with a large thrombus burden. (See "Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction", section on 'Thrombectomy'.)

Heparin preferred to bivalirudin for primary PCI (August 2014)

The recommended anticoagulant strategy in patients with ST-elevation myocardial infarction (STEMI) who are treated with primary percutaneous coronary intervention (PCI) continues to evolve. In recent years bivalirudin has been the preferred agent. In the HEAT-PPCI single center trial, unfractionated heparin (UFH) was directly compared to bivalirudin in 1829 such patients [12]. The use of glycoprotein IIb/IIIa inhibitors was about 15 percent in both groups and all patients received a potent oral P2Y12 platelet receptor blocker (ticagrelor or prasugrel). The primary efficacy outcome, a
composite of all-cause mortality, cerebrovascular accident, reinfarction, or additional unplanned target lesion revascularization, occurred significantly more often in the bivalirudin group (8.7 versus 5.7 percent), while the rate of bleeding did not differ significantly. For STEMI patients undergoing primary PCI who receive a potent P2Y12 receptor blocker, we now prefer UFH rather bivalirudin. Furthermore, glycoprotein IIb/IIIa inhibitors do not appear to be routinely indicated with UFH. (See "Anticoagulant therapy in acute ST elevation myocardial infarction", section on 'UFH compared to bivalirudin'.)

CORONARY HEART DISEASE, STABLE

Optimal duration of dual antiplatelet therapy after coronary stenting (December 2014)

All patients who undergo percutaneous coronary intervention with stenting receive dual antiplatelet therapy (DAPT), which is the combination of aspirin and a P2Y12 receptor blocker. However, the optimal duration of DAPT is not known; 12 months has been the commonly recommended duration. The DAPT trial randomly assigned 9961 such patients, who had been successfully treated with 12 months of aspirin and a P2Y12 receptor blocker (either clopidogrel or prasugrel), to continue receiving the P2Y12 receptor blocker or placebo for another 18 months; all patients continued aspirin [13]. The rates for each of the co-primary end points of stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death from any cause, MI, or stroke) were lower with continued P2Y12 therapy (0.4 versus 1.4 percent and 4.3 versus 5.9 percent). However, the rate of moderate or severe bleeding was increased (2.5 versus 1.6 percent). Based on available evidence, including the DAPT trial, we recommend DAPT for 12 months in patients not at high risk of bleeding, which is the major complication of this therapy. After 12 months of uncomplicated DAPT therapy, we suggest an additional 18 months of treatment. (See "Antiplatelet therapy after coronary artery stenting", section on 'Drug-eluting stents'.)

Risk of myocardial infarction and nonobstructive coronary heart disease (November 2014)

Given the slow progression of atherosclerosis, patients with coronary heart disease (CHD) may be asymptomatic for years, and the prognosis related to nonobstructive coronary lesions is uncertain. Nonobstructive CHD refers to stenosis ≥20 percent but <70 percent, while obstructive CHD is identified when at least one stenosis is ≥70 percent. In a retrospective cohort study of over 37,000 patients (96 percent male) without prior CHD events who underwent elective coronary angiography and were followed for one year, the risk of myocardial infarction (MI) increased with the extent of both nonobstructive and obstructive lesions [14]. Compared to patients without CHD, the risk of MI trended higher for patients with one vessel nonobstructive CHD and was significantly greater for two and three vessel nonobstructive CHD. Patients found to have nonobstructive CHD should be treated with usual secondary prevention measures. (See "Epidemiology of coronary heart disease", section on 'Non-obstructive CHD'.)

Ivabradine not effective for stable angina (September 2014)

Over the past two decades there have been no important additions to options for medical therapy of angina pectoris aside from ranolazine. In early trials, the chronotropic drug ivabradine appeared to improve symptoms of angina. However, the SIGNIFY trial, which randomly assigned over 19,000 patients with stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more to ivabradine or placebo, found no difference in the composite end point of
cardiovascular death or nonfatal myocardial infarction [15]. Additionally, among patients with Canadian Cardiovascular Society class II angina or higher, the composite outcome occurred significantly more often in the group treated with ivabradine. Based on these results, we do not recommend the use of ivabradine in patients with stable angina who do not have clinical heart failure. (See "New therapies for angina pectoris", section on 'Ivabradine'.)

**Beta blockers in stable coronary heart disease (August 2014)**

Although beta blocker therapy improves survival in patients who have sustained an acute myocardial infarction (MI), there is no convincing evidence for this benefit in patients with stable disease. In an observational study of over 26,000 patients discharged after a first coronary heart disease event (an acute coronary syndrome or coronary artery revascularization) and followed for nearly four years, there was no difference in the risk of death in the subgroup without recent MI between those who did or did not receive beta blocker [16]. In patients with stable coronary heart disease who have not had a recent acute MI, beta blockers are indicated to treat angina but not to improve survival. (See "Secondary prevention of cardiovascular disease", section on 'Beta blockers'.)

**HEART FAILURE**

**Beta-blocker therapy in patients with atrial fibrillation and heart failure (September 2014)**

An individual patient data meta-analysis of patients with heart failure (predominantly due to systolic dysfunction) found that beta blocker therapy did not reduce mortality in patients with atrial fibrillation, though it reduced mortality in patients in sinus rhythm [17]. This meta-analysis raises questions about the role of beta blockers as standard therapy to improve prognosis in patients with atrial fibrillation and systolic heart failure, though these results are not sufficient to change our treatment recommendations at this time. (See "Use of beta blockers in heart failure due to systolic dysfunction", section on 'General approach'.)

**Neprilysin inhibitor plus angiotensin II receptor blocker in systolic heart failure (September 2014)**

A randomized double-blind trial in patients with systolic heart failure found that sacubitril-valsartan (LCZ696) reduced the primary outcome of cardiovascular mortality and hospitalization for heart failure and also reduced all-cause mortality compared to a proven dose of the ACE inhibitor enalapril [18]. Sacubitril-valsartan is an investigational drug combining the neprilysin inhibitor sacubitril (which raises natriuretic peptide levels) and the angiotensin II receptor blocker valsartan. The sacubitril-valsartan group had higher rates of hypotension and nonserious angioedema but lower rates of renal impairment, hyperkalemia, and cough compared to the enalapril group. (See "Angiotensin II receptor blocker and neprilysin inhibitor therapy in heart failure due to systolic dysfunction", section on 'Rationale'.)

**LIPID DISORDERS**

**Lower HMG CoA reductase activity increases risk of diabetes (January 2015)**

A Mendelian randomization study found that decreased genetic HMG CoA reductase activity is associated with a higher risk of type 2 diabetes, such that at least some of the risk of diabetes seen
with statin therapy appears to be due to its inhibition of HMG CoA reductase [19]. Since this inhibition is thought responsible for the primary efficacy of statin therapy, this finding means that any effective statin will probably increase the risk of diabetes [20]. (See "Statins: Actions, side effects, and administration", section on 'Diabetes mellitus'.)

**Evolocumab for drug-resistant hypercholesterolemia (November 2014)**

In the past two years, multiple randomized trials have found that monoclonal antibodies to PCSK9 (a protease produced in the liver that degrades hepatocyte low density lipoprotein receptors) significantly lower low density lipoprotein-cholesterol (LDL-C) levels in patients with drug-resistant hypercholesterolemia. Two placebo-controlled studies in patients on stable lipid lowering therapy, TESLA Part B and RUTHERFORD-2, provide additional evidence for the efficacy and safety of evolocumab, one such drug in this class. TESLA Part B randomly randomized 50 patients with homozygous familial hypercholesterolemia (FH) [21] and RUTHERFORD-2 randomized 331 patients with heterozygous FH [22]. In these studies, evolocumab lowered LDL-C by 31 and 60 percent, respectively; no new safety concerns were identified. Evolocumab is currently an investigational drug. (See "Inherited disorders of LDL-cholesterol metabolism" and "Treatment of drug-resistant hypercholesterolemia".)

**Statin-associated adverse muscle events (October 2014)**

Terminology around statin-associated adverse muscle events is variable and has changed over time. The 2014 National Lipid Association Statin Muscle Safety Task Force has proposed new definitions for these adverse events [23], which are reflected in our discussion of statin myopathy. Additionally, we no longer suggest a trial of Coenzyme Q10 (CoQ10) for patients experiencing such statin-associated adverse muscle events. (See "Statin myopathy", section on 'Coenzyme Q10' and "Statin myopathy", section on 'Definitions'.)

**MYOPERICARDIAL DISEASE**

**Hereditary transthyretin amyloid cardiomyopathy in older African-Americans (January 2015)**

One of the most common hereditary transthyretin amyloid cardiomyopathies is caused by the Val122Ile mutation. This mutation is present in 3 to 4 percent of the African-American population but the penetrance of disease caused by this mutation is uncertain. A prospective community-based observational study of 124 carriers and 3732 noncarriers suggested that the penetrance of disease caused by the Val122Ile mutation is low [24]. After over two decades of follow-up starting at a median age of 53 years, there was no significant difference in mortality between carriers and noncarriers although the risk of incident heart failure was increased in carriers. (See "Clinical manifestations and diagnosis of amyloid cardiomyopathy", section on 'TTR mutation'.)

**Corticosteroids of limited benefit in tuberculous pericarditis (September 2014)**

Whether corticosteroids are beneficial for patients with tuberculous pericarditis has been controversial. A randomized trial including 1400 adults initiating antimicrobial treatment for definite or probable tuberculous pericarditis in South Africa (approximately two-thirds of patients had concomitant HIV infection) demonstrated no effect of adjunctive corticosteroids on the primary composite efficacy outcome of death, cardiac tamponade requiring pericardiocentesis, or
development of constrictive pericarditis [25]. Corticosteroid use did reduce the incidence of constrictive pericarditis alone (4.4 versus 7.8 percent). The overall lack of benefit may have reflected harm from corticosteroid treatment in patients with HIV, and it remains possible that patients without HIV could benefit from corticosteroids. Based on the totality of the evidence, we do not routinely use adjunctive corticosteroids in the absence of constrictive disease or high risk for constrictive disease. This approach is in disagreement with prior guidelines favoring routine use of corticosteroids for all patients with tuberculous pericarditis.

We continue to suggest administration of corticosteroids for patients with constrictive tuberculous pericarditis and for those felt to be at high risk of developing the condition (i.e., large effusion, high level of pericardial fluid inflammatory cells, or early signs of constriction). (See "Tuberculous pericarditis", section on ‘Role of corticosteroids’.)

PREVENTIVE CARDIOLOGY

Running and cardiovascular risk (August 2014)

Several professional society guidelines recommend at least 30 minutes of moderate-intensity exercise five to seven days per week, but this is not achievable for all patients. In a prospective cohort study with a mean follow-up of over 15 years, over 55,000 adults (mean age 44 years) reported duration, distance, frequency, and speed of any running or jogging [26]. Runners had significantly lower risks of all-cause and cardiovascular mortality compared to non-runners. Additionally, the derived mortality benefit was similar for all runners regardless of the total running time, including for those who ran less than 51 minutes per week. These findings from a non-randomized study may represent unidentified confounding factors, and do not prove causation. However, these data support the concept that even small amounts of exercise are better than no exercise while at least 30 minutes of moderate-intensity exercise five to seven days per week remains a reasonable goal for most patients. (See "Exercise and fitness in the prevention of cardiovascular disease", section on ‘Type, intensity, and duration of exercise’.)

REVASCULARIZATION

Optimal duration of dual antiplatelet therapy after coronary stenting (December 2014)

All patients who undergo percutaneous coronary intervention with stenting receive dual antiplatelet therapy (DAPT), which is the combination of aspirin and a P2Y₁₂ receptor blocker. However, the optimal duration of DAPT is not known; 12 months has been the commonly recommended duration. The DAPT trial randomly assigned 9961 such patients, who had been successfully treated with 12 months of aspirin and a P2Y₁₂ receptor blocker (either clopidogrel or prasugrel), to continue receiving the P2Y₁₂ receptor blocker or placebo for another 18 months; all patients continued aspirin [13]. The rates for each of the co-primary end points of stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death from any cause, MI, or stroke) were lower with continued P2Y₁₂ therapy (0.4 versus 1.4 percent and 4.3 versus 5.9 percent). However, the rate of moderate or severe bleeding was increased (2.5 versus 1.6 percent). Based on available evidence, including the DAPT trial, we recommend DAPT for 12 months in patients not at high risk of bleeding, which is the major complication of this therapy. After 12 months of uncomplicated DAPT
therapy, we suggest an additional 18 months of treatment. (See "Antiplatelet therapy after coronary artery stenting", section on 'Drug-eluting stents'.)

**VALVULAR HEART DISEASE**

**Surgery for moderate ischemic mitral regurgitation (December 2014)**

Ischemic mitral regurgitation (MR) is associated with increased risk of heart failure and mortality. However, the benefit of performing mitral valve repair at the time of coronary artery bypass grafting (CABG) is uncertain. In a multicenter trial, 301 patients with moderate ischemic MR were randomly assigned to CABG alone or CABG plus mitral valve repair [27]. At one year follow-up, the degree of reverse remodeling, functional status, and mortality rates were the same in the two groups. The combined procedure group had a lower prevalence of moderate or severe MR but a longer bypass time, a longer hospital stay after surgery, and more neurologic events. Longer follow-up is needed to determine whether the reduction in MR leads to long-term clinical benefit. (See "Ischemic mitral regurgitation", section on 'Moderate to severe MR'.)

**Genetic predisposition to hyperlipidemia associated with aortic valve disease (December 2014)**

Plasma low-density lipoprotein cholesterol (LDL-C) is associated with risk of calcific aortic valve disease but the genetic contribution to this risk is uncertain. A Mendelian randomization study found an association between the weighted genetic risk score (GRS, a measure of the genetic predisposition to elevation in plasma lipids) for low-density lipoprotein cholesterol (LDL-C) and aortic valve calcium in 6942 participants in community-based studies [28]. The LDL-C GRS was also associated with incident aortic stenosis in a separate community-based population. Trials of lipid lowering therapies in patients with aortic stenosis have not shown convincing benefit but the potential effect of lipid lowering therapy initiated earlier is uncertain. (See "Aortic valve sclerosis and pathogenesis of calcific aortic stenosis", section on 'Genetic factors'.)

**OTHER CARDIOLOGY**

**Icatibant for ACE-inhibitor associated angioedema (February 2015)**

Angiotensin-converting enzyme (ACE) inhibitors cause episodic, bradykinin-mediated angioedema in less than 1 percent of recipients, but this accounts for approximately one-third of angioedema cases presenting to emergency departments in countries where these medicines are widely used. The most common approach to management of severe episodes affecting the airway has been discontinuation of the ACE inhibitors and supportive care, which may involve intubation and even tracheotomy. Icatibant, a bradykinin receptor antagonist approved for use in hereditary angioedema, has now been shown to be effective for ACE inhibitor-associated angioedema [29]. In a randomized trial of 27 adults presenting to the emergency department with angioedema of the upper aerodigestive tract while taking an ACE inhibitor, patients received one dose of icatibant or standard therapy (an intravenous glucocorticoid plus an antihistamine). Symptoms in the icatibant group resolved in a median of 8 hours, compared with 27 hours in the glucocorticoid/antihistamine group, and icatibant was well tolerated. Icatibant is most likely to be effective if given in the first few hours of an angioedema attack when the swelling is still increasing. (See "ACE inhibitor-induced angioedema", section on 'Icatibant'.)
Increased serum digoxin in patients taking dronedarone (November 2014)

Digoxin, because of its pharmacologic properties, is subject to numerous drug-drug interactions which alter its availability and potentially lead to toxicity. The PALLAS trial randomized patients with permanent atrial fibrillation to dronedarone or placebo in addition to usual care, and found an increase in cardiovascular death with dronedarone. A subgroup analysis was done to determine if adverse events correlated with use of digoxin [30]. Among patients who had been taking digoxin at baseline, digoxin levels during the trial were higher in patients taking dronedarone than placebo. Additionally, there were more cardiovascular deaths in patients co-administered dronedarone and digoxin compared to placebo and digoxin. When dronedarone and digoxin are co-administered, the digoxin dose should be reduced by 50 percent, and digoxin levels should be monitored closely to maintain serum concentrations of 0.5–0.8 ng/mL. (See "Clinical uses of dronedarone", section on 'Metabolism and drug interactions'.)

Investigational agent for reversal of multiple anticoagulants (November 2014)

Reversal agents for the target specific oral anticoagulants are lacking. In a study of 80 healthy volunteers given a therapeutic dose of the direct factor Xa inhibitor edoxaban, a reversal agent under development (PER977) normalized the whole blood clotting time within 10 minutes; in contrast, normalization of the clotting time took 12 to 15 hours in individuals given edoxaban followed by placebo [31]. In addition to binding direct factor Xa inhibitors, PER977 also binds the direct thrombin inhibitor dabigatran, as well as unfractionated and low molecular weight heparins. (See "Management of bleeding in patients receiving target-specific oral anticoagulants", section on 'Antidotes under development'.)

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

Library Opening Times

Staffed times 8.30 am—16.30 pm
Monday to Friday

Swipe Access 7.00 am—23.00pm
7 days a week

Level 5,
Education Centre
University Hospitals Bristol

Contact your outreach librarian
Helen Pullen
library@UHBristol.nhs.uk